Keyword: Crestor

Between Seroquel, Nexium and Crestor, AstraZeneca investors may have felt over the past few years that the extended fall off the patent cliff would never stop smarting. But the company promises things will turn around if they’ll just hang on.

AstraZeneca’s Crestor stands at the top of the cardiovascular drugs heap for 2016, but 2017 will be a different story. Generic versions of the med hit the U.S. market last year after a last-ditch court fight against the FDA, and the brand immediately lost share to the cheaper copycats.